Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKPRNewsWire • 02/26/24
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral InfectionsPRNewsWire • 02/07/24
Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024PRNewsWire • 01/04/24
Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023PRNewsWire • 10/31/23
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell TechnologyPRNewsWire • 10/11/23
Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene TherapiesPRNewsWire • 10/09/23
Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual MeetingPRNewsWire • 10/04/23
Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 InfectionPRNewsWire • 09/14/23
Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research EndowmentPRNewsWire • 09/11/23
Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical OfficerPRNewsWire • 08/30/23
Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra TherapeuticsPRNewsWire • 08/17/23
Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion DiagnosticPRNewsWire • 08/01/23
Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten OfferingPRNewsWire • 06/16/23
Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten OfferingPRNewsWire • 06/14/23
Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature CommunicationsPRNewsWire • 05/10/23
Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra TherapeuticsPRNewsWire • 04/18/23
Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment StrategiesPRNewsWire • 03/29/23
Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational MedicinePRNewsWire • 03/21/23
Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short SellingPRNewsWire • 02/07/23